ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Trazodone

Also written as “Trazodone HCl”, “Trazodone 20 mg” and “150 mg trazodone hydrochloride”.

Its studies are mostly in Depression · Diabetic Neuropathies · Depressive Disorder, Major · Sleep Wake Disorders, led by 4 companies.

Drug pageTrazodone: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 12, 201414 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Angelini Pharmaits history only50 open or runningphase 3since Mar 12, 2014Mar 12, 2014none ahead
Labopharm50 open or runningphase 3since Oct 17, 2008Oct 17, 2008none ahead
Lee's Pharmaceuticalits history only30 open or runningphase 3since Jan 13, 2012Jan 13, 2012none ahead
Targeted Medical Pharmaits history only10 open or runningphase 3since Nov 5, 2011Nov 5, 2011none ahead

Also a collaborator on its studies: Chiltern International, Cross Research, eResearch Technology and Algorithme Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Labopharm only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 17, 2008First study: phase 3 study in Depressive Disorder, MajorFirst studyNCT00775203 · 412 enrolled · United States, Canada
  2. Feb 6, 2009Phase 1 study in HealthyNCT00839072 · 24 enrolled · Canada
  3. May 10, 20103 phase 1 studiesNCT01121926, NCT01121913, NCT01121900

TargetBeta

“Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule

Studies

All 5 Labopharm leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01121926Healthy Subjects1CompletedMar 200830
NCT01121913Healthy1CompletedApr 200524
NCT01121900Healthy1CompletedJul 200826
NCT00839072Healthy · Canada1CompletedFeb 200924
NCT00775203Depressive Disorder, Major · United States, Canada3CompletedNov 2007412

How it is read

Names in the registry

  • “Trazodone HCl”, 10 entries
  • “Trazodone”, 3 entries
  • “Trazodone 20 mg”, 2 entries
  • “150 mg trazodone hydrochloride”, 1 entry
  • “300 mg trazodone hydrochloride”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.